Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

被引:76
作者
Kreuzer, KA
le Coutre, P
Landt, O
Na, LK
Schwarz, M
Schultheis, K
Hochhaus, A
Dörken, B
机构
[1] Humboldt Univ, Univ Klinikum Charite, Virchow Klinikum, Med Klin Hamatol & Onkol, D-13353 Berlin, Germany
[2] TIB Molbiol Inc, Berlin, Germany
[3] Heidelberg Univ, Fak Klin Med Mannheim, Med Klin 3, Heidelberg, Germany
关键词
chronic myeloid leukemia; imatinib; resistance; peptide nucleic acid; PCR;
D O I
10.1007/s00277-003-0644-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently, various mutations within the Abl sequence have been described that negatively affect imatinib binding to Bcr/Abl resulting in cellular resistance of chronic myeloid leukemia (CML) cells. So far, little is known as to whether these mutations are preexisting or develop under imatinib therapy as current mutation analyses are limited by a low sensitivity of approximately 1:2 (50%) to 1:5 (20%). By combining peptide nucleic acid (PNA)-based DNA clamping with a fluorescence hybridization probe assay, we developed a new and highly sensitive technique for the detection of known mutations within the Bcr/Abl kinase domain. With this approach we investigated 19 cases of CML refractory to imatinib treatment before and during therapy. By clamping of wild-type Abl through PNA we could effectively enhance the detection sensitivity for the Bcr/Abl mutations Thr315Ile, Glu255Lys, and Tyr253His such that I mutant cDNA molecule could be detected in 500 negatives (0.2%). We observed in one case that a Gly255Lys mutation was detectable before treatment. By DNA analysis of buccal swaps, a genetic polymorphism could be excluded. In two cases clonal evolution of known mutations developed gradually under treatment. In another case an initially detectable Tyr253His mutation disappeared after therapy onset but was again observed after 6 weeks of imatinib treatment. Preexisting and evolving Bcr/Abl mutations associated with an unfavorable prognosis could be safely detected by the presented technique. This may facilitate risk stratification in CML and may serve as a model for individualized molecular monitoring and therapeutic strategies in other malignant diseases.
引用
收藏
页码:284 / 289
页数:6
相关论文
共 22 条
[1]   High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [J].
Branford, S ;
Rudzki, Z ;
Walsh, S ;
Grigg, A ;
Arthur, C ;
Taylor, K ;
Herrmann, R ;
Lynch, KP ;
Hughes, TP .
BLOOD, 2002, 99 (09) :3472-3475
[2]   Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].
Druker, BJ ;
Tamura, S ;
Buchdunger, E ;
Ohno, S ;
Segal, GM ;
Fanning, S ;
Zimmermann, J ;
Lydon, NB .
NATURE MEDICINE, 1996, 2 (05) :561-566
[3]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[4]   In vitro transcription and translation inhibition by anti-promyelocytic leukemia (PML)/retinoic acid receptor alpha and anti-PML peptide nucleic acid [J].
GambacortiPasserini, C ;
Mologni, L ;
Bertazzoli, C ;
LeCoutre, P ;
Marchesi, E ;
Grignani, F ;
Nielsen, PE .
BLOOD, 1996, 88 (04) :1411-1417
[5]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880
[6]  
Hochhaus A, 2001, SCIENCE, V293, P2163
[7]   Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation [J].
Hofmann, WK ;
Jones, LC ;
Lemp, NA ;
de Vos, S ;
Gschaidmeier, H ;
Hoelzer, D ;
Ottmann, OG ;
Koeffler, HP .
BLOOD, 2002, 99 (05) :1860-1862
[8]  
Kreil S, 2001, BLOOD, V98, p435A
[9]  
Kreuzer KA, 2000, INT J CANCER, V86, P741, DOI 10.1002/(SICI)1097-0215(20000601)86:5<741::AID-IJC22>3.0.CO
[10]  
2-1